Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
November 06, 2018 16:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following investor conferences...
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 01, 2018 17:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 26, 2018, the Compensation Committee of the Board of...
Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting
November 01, 2018 16:03 ET
|
Portola Pharmaceuticals, Inc.
– Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies – – Also Accepted: Two Posters on Andexxa® and an Oral Session on the Burden of...
Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018
October 23, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s...
Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis
October 09, 2018 09:05 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its 2018 partnership with the World Thrombosis Day campaign to help raise...
Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma
September 25, 2018 16:38 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer
September 20, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
– Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise – – Commercial responsibility for two of the industry’s most successful...
U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process
September 11, 2018 18:06 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt...
Portola Pharmaceuticals Announces Executive Leadership Change
September 07, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective September...
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 05, 2018 18:15 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of...